Vaxcyte said it will host a webcast and conference call on Oct. 5, 2026, at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from OPUS-1, its adult pivotal Phase 3 trial of VAX-31.

The company said the study is evaluating the safety, tolerability and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease and pneumococcal pneumonia.

To join the call, participants can dial 800-445-7795 in the US or 785-424-1699 internationally and use conference ID PCVX1005. A live webcast will also be available on Vaxcyte's investor relations page at www.vaxcyte.com.

Vaxcyte said the webcast will remain archived on its website for at least 30 days after the live event.

ประเด็นสำคัญ

  • The webcast and call are set for 8:00 a.m. ET / 5:00 a.m. PT on Oct. 5, 2026.
  • Vaxcyte plans to present topline data from the OPUS-1 adult pivotal Phase 3 trial.
  • The trial is evaluating the safety, tolerability and immunogenicity of VAX-31.